Skip to content
Company Analysis

Aytu BioPharma, Inc. AYTU

A comprehensive view of key metrics, scores, and financial health for Aytu BioPharma, Inc.

Overview of Aytu BioPharma, Inc.

AYTU NCM
Healthcare Drug Manufacturers - Specialty & Generic Micro Cap
Aytu BioPharma, Inc. (AYTU), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $2.54, about 308.3% undervalued vs fair value, +106.5% 1Y return, ranked 836/1110 in sector.
$2.54
-3.79%
As of March 13, 2026
Previous close • Vol 90d: 52.9%
52-Week Range
Market Cap
$27.26M
Enterprise Value
$18.17M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Aytu BioPharma, Inc..

Top Beats

Quick Facts

Website https://aytubio.com
HQ Denver, CO
Employees 82
Fiscal year Jun 30

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$9
$10
$12
Current: $2.54 +308% vs base

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$66.4M
1.8%%
Gross Profit
$45.8M
-6.6%%
R&D Expense
$1.3M
-52.1%%
Operating Income (EBIT)
$-10.0M
-88.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
2.0%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Aytu BioPharma, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
53
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
55
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing AYTU's balance between Growth (28.0%), Profitability (39.5%), and Safety (32.5%). Growth 28% Safety 32% Profitability 40%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

34th percentile vs peers
35
Key Signals
Rev Growth YoY 1.8% 40p EPS Growth YoY 24.5% 47p Revenue CAGR 3Y -11.8% 18p
Strengths
  • D/E Ratio in top 20% of peers (1.15, 85th percentile)
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

49th percentile vs peers
49
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

40th percentile vs peers
41
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Aytu BioPharma, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$10.37
- - -
+308.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info